

12 December 2023

Treatments for Bladder Cancer

In the past three months, how many patients have been treated for Bladder cancer with the below:

- a) Avelumab: <5**
- b) Atezolizumab: <5**
- c) Carboplatin with Gemcitabine: <5**
- d) Carboplatin single or in any other combination: Carboplatin +
Etoposide <5**
- e) Cisplatin with Gemcitabine: <5**
- f) Cisplatin single or in any other combination: Cisplatin + Etoposide
<5**
- g) Nivolumab: <5**
- h) Pembrolizumab: <5**
- i) Any other systemic anti-cancer therapy: <5**
- j) Palliative care only: Not recorded**

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.